[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$gubra
$GUBRA's related obesity molecule advances in development with Boehringer Ingelheim, sparking significant social media buzz. The project is also advancing its own UCN2 molecule into Phase X trials.
About $gubra
$GUBRA is a digital asset and blockchain project focused on decentralized finance.
Insights
- $gubra engagements is up 2645.65% from the previous week.
- $gubra mentions is up XXXXX% from the previous week.
Engagements: XXX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXX
X Week: XXXXX +2,646%
X Month: XXXXXX -XX%
X Months: XXXXXXX -XX%
X Year: XXXXXXX +4%
1-Year High: XXXXXX on 2025-03-12
1-Year Low: X on 2025-09-08
Engagements by network (24h): X: XXX
Mentions: X (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: X +67%
X Month: XX -XX%
X Months: XXX +19%
X Year: XXX +33%
1-Year High: XX on 2025-08-08
1-Year Low: X on 2025-01-28
Mentions by network (24h): X: XX
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $gubra in the last XX hours which is no change from in the previous XX hours
Daily Average: X
X Week: X no change
X Month: X -XX%
X Months: XX -XX%
X Year: XX +39%
1-Year High: XX on 2025-08-08
1-Year Low: X on 2024-12-25
The most influential creators that mention $gubra in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @doepke_michel | X | XXXXX | X | XXX |
| @ResearchPulse1 | X | XXXXX | X | XX |
Top $gubra Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Boehringer Ingleheim advance first in class tripple agonist to P2 in obesity. Its a GLP1/GIP/NPY2. So will be very interesting to see data. But since BI is an unlisted BP I guess we will not get any more details This is $GUBRA molecule and their X obesity molecule in development. The most know of course is their Amylin. $GUBRA has X obesity programs with BI and this is the second in trials. GUBRA will in Q1 get their 4th obesity molecule UCN2 in P1. Thats still XXX% owned by GUBRA self. $LLY $NVO $VKTX"
X Link @ResearchPulse1 2025-12-08T07:52Z 2038 followers, 1213 engagements
"$GUBRA #BoehringerIngelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development. $LLY $NVO $VKTX $ABBV"
X Link @doepke_michel 2025-12-08T07:05Z 5926 followers, 1383 engagements
"What else can $ABBV say Rinvoq and Skyrizi are THE growth drivers in the portfolio following the Humira patent cliff. Competition is not welcome here - I can imagine that AbbVie will purchase/license further assets in this area and in the field of obesity. $ABVX $GUBRA"
X Link @doepke_michel 2025-12-04T14:48Z 5928 followers, 2892 engagements
"Interesting. $ABBV already partnered with $GUBRA (amylin) this year. Who's next $LLY $NVO $VKTX $GPCR"
X Link @doepke_michel 2025-12-03T16:44Z 5927 followers, 7140 engagements